References
- Baigent C, Keech A, Kearney PM et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
- Brown MS, Goldstein JL. Biomedicine. Lowering LDL–not only how low, but how long? Science 311(5768), 1721–1723 (2006).
- Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178(5), 576–584 (2008).
- Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841), 581–590 (2012).
- Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat. Rev. Endocrinol. 5(9), 507–518 (2009).
- Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J. Am. Coll. Cardiol. 59(19), 1697–1705 (2012).
- Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 409(6818), 307–312 (2001).
- Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 88(11), 5452–5455 (2003).
- Azuma K, Katsukawa F, Oguchi S et al. Correlation between serum resistin level and adiposity in obese individuals. Obes. Res. 11(8), 997–1001 (2003).
- Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz Wika J, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metab. Clin. Exp. 57(4), 488–493 (2008).
- Curat CA, Wegner V, Sengenès C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49(4), 744–747 (2006).
- Rosenson RS. Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. Curr. Opin. Cardiol. 20(4), 313–317 (2005).
- Quilliam BJ, Perez HE, Andros V, Jones P. Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. J. Manag. Care Pharm. 10(3), 244–250 (2004).
- Vega GL, Grundy SM. Effect of statins on metabolism of apoB-containing lipoproteins in hypertriglyceridemic men. Am. J. Cardiol. 81(4A), 36B–42B (1998).
- Costandi J, Melone M, Zhao A, Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ. Res. 108(6), 727–742 (2011).
- Owecki M, Nikisch E, Miczke A, Pupek-Musialik D, Sowinski J. Serum resistin is related to plasma HDL cholesterol and inversely correlated with LDL cholesterol in diabetic and obese humans. Neuro. Endocrinol. Lett. 31(5), 673–678 (2010).
- de Luis DA, Sagrado MG, Conde R et al. Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naïve diabetes obese patients. Diabetes Res. Clin. Pract. 89(2), 110–114 (2010).
- Fazio S, Linton MF. Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol: a case for resistin. J. Am. Coll. Cardiol. 59(19), 1706–1708 (2012).
- Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7), 932–939 (2005).
- Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 304(5674), 1154–1158 (2004).